ADHD Prescribing Just Got Harder: New DEA Requirements Explained

What You’ll Learn

The DEA has tightened requirements around controlled substance prescribing, and ADHD stimulant management is at the center of it. In this free webinar, Lindsay sits down with Dr. Lauren Grauert to break down what’s changed, why it matters, and how to adjust your clinical practice.

Whether you’re prescribing stimulants in outpatient, telehealth, or private practice, this session covers the practical compliance and clinical decision-making updates every PMHNP needs to know.

Topics Covered

• New DEA Guidelines — What’s changed in 2026 and how it impacts your day-to-day prescribing of controlled substances
• ADHD Stimulant Prescribing — Updated requirements for initiating and maintaining stimulant medications (amphetamine salts, methylphenidate, lisdexamfetamine)
• Controlled Substance Contracts — Best practices for treatment agreements, what to include, and how to document appropriately
• Heightened Scrutiny & Compliance — How to protect yourself and your practice under increased regulatory oversight
• Drug Administration & Medication Safety — Safe prescribing frameworks, PDMP checks, and risk mitigation strategies
• Patient Care Best Practices — Balancing access to necessary ADHD treatment with regulatory compliance

Featured Guest

Dr. Lauren Grauert joins Lindsay for this discussion, bringing expertise on the evolving regulatory landscape around controlled substance prescribing and practical strategies for staying compliant while providing excellent patient care.

Who This Is For

This webinar is essential for any PMHNP who prescribes stimulants or other controlled substances — especially if you work in telehealth, private practice, or outpatient settings where DEA scrutiny has increased. If you’ve been unsure about the new requirements or how to update your controlled substance agreements, this session clears it all up.